The following articles (labelled with PubMed ID or TBD) are for your review
||Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation.
||Pfizer Global Research and Development
||2-(3-Methyl-3H-diaziren-3-yl)ethyl 1-(1-phenylethyl)-1H-imidazole-5-carboxylate: a derivative of the stereoselective general anesthetic etomidate for photolabeling ligand-gated ion channels.
||Massachusetts General Hospital
||Emerging molecular approaches to pain therapy.
||Identification and initial structure-activity relationships of (R)-5-(2-azetidinylmethoxy)-2-chloropyridine (ABT-594), a potent, orally active, non-opiate analgesic agent acting via neuronal nicotinic acetylcholine receptors.
||Neuronal nicotinic acetylcholine receptors as targets for drug discovery.
||(S)-(-)-5-ethynyl-3-(1-methyl-2-pyrrolidinyl)pyridine maleate (SIB-1508Y): a novel anti-parkinsonian agent with selectivity for neuronal nicotinic acetylcholine receptors.
||SIBIA Neurosciences Inc.
||Total synthesis of pyrrolizidines 223H', 239K', 265H', and 267H' found in Madagascan frogs (Mantella) and their affinities for nicotinic acetylcholine receptor.
||Toyama Medical and Pharmaceutical University
||Bis-catechol-substituted redox-reactive analogues of hexamethonium and decamethonium: stimulated affinity-dependent reactivity through iron peroxide catalysis.
||University of Toledo
||Synthesis and biological characterization of pyridohomotropanes. Structure-activity relationships of conformationally restricted nicotinoids.
||Stauffer Chemical Company
||Structure/activity and molecular modeling studies of the lophotoxin family of irreversible nicotinic receptor antagonists.
||University of California-San Diego